Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1826 results
May 2018
-
Press release
Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
Alcon Cares to donate 100 reprocessed Infiniti® units to clinics helping underserved patients in Asia, Central and South America, and Africa over the next three years Program to increase… -
Press release
AveXis Reports First Quarter 2018 Financial and Operating Results
-- Significant progress across operating functions including licensing, clinical trials and regulatory interactions -- -- AVXS-101 pre-BLA meeting with FDA is scheduled to be… -
Ad hoc release
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
Holzkirchen, May 2, 2018 - Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing… -
Story Patient Perspectives
T.J. Sharpe on why clinical trials matter
Melanoma survivor T.J. Sharpe discusses the importance of clinical trials to help raise awareness among the community.
-
Press release
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only… -
Ad hoc release
Novartis provides update on proposed acquisition of AveXis
Basel, May 1, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") applicable to…
April 2018
-
Press release
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
Tafinlar + Mekinist is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection… -
Press release
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week… -
In The News
How Long Till the Final World Malaria Day?
Deaths from malaria have been driven down by 60% since 2000. But unchecked drug resistance could cause more than 100,000 new deaths each year. Vas Narasimhan, CEO of Novartis, explains how we could… -
Press release
AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
CHICAGO, April 25, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening… -
Press release
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible Using patients' self-recorded measurements, FocalView aims to… -
Press release
AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
– A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial – – All patients in the therapeutic dose cohort in the Phase 1 trial…